Ireland Hesitates on Life-Saving Drug | Cork News

Ireland faces a heartbreaking dilemma as it hesitates to fund a life-changing drug for Friedreich’s ataxia, a rare disease affecting 200 people — despite eleven European nations already approving it. The HSE’s drug group has recommended against funding Skyclarys, citing cost concerns around €280,000 per patient annually, while families and politicians like TD John McGuinness and Sinn Féin’s Mary Lou McDonald argue this is an investment in human lives, not just healthcare expenses. With the final decision looming on August 25th, patients and their loved ones are pleading for urgent action — asking Ireland to match its European neighbors and give these young people the chance to live fuller, healthier lives. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/523f7a1ebb342047